

COHEN, PONTANI, LIEBERMAN & PAVANE **FAX RECEIVED**

COUNSELORS AT LAW
PATENTS, TRADEMARKS & COPYRIGHTS
551 FIFTH AVENUE
NEW YORK, NEW YORK 10176
TELEPHONE: 212-687-2770
FACSIMILE: 212-672-5487

APR 09 2002

GROUP 1600

FACSIMILE TRANSMISSION

OFFICIAL

From: Kent H. Cheng
Pages: 7 (including this page)

Date: 4/8/02 5:29 PM
Our File: 4830-15

Please deliver to:

Examiner B. Badio	U.S. PTO - Group 1616	1-703-872-9307
-------------------	-----------------------	----------------

☐ Confirmation Will Follow☐ Confirmation Will Not Follow

Notes/Comments:

In re Application of

Perry Calias et al.

Serial No.: 09/543,489

Filed: April 06, 2000

For: Immunomodulatory Compositions and Methods of Use Thereof

This transmission may contain information which is privileged, constitutes attorney work product, or is otherwise protected from disclosure. Its contents are confidential and intended for the addressee only, and must not be used, copied, or disseminated by any person other than the addressee. The recipient is requested to notify the sender immediately of any error in transmission and to destroy any transmission not intended for the recipient. If you do not receive all pages or otherwise experience transmission difficulties, please call us at (212) 687-2770.

15/B (rev)

Attorney Docket # 4830-15

PATENT


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Perry Calias et al.

Serial No.: 09/543,489

Filed: April 06, 2000

For: Immunomodulatory Compositions and Methods
of Use ThereofExaminer: B. Badio
Group Art: 1616Bet
4-12-02Assistant Commissioner for Patents
Washington, D.C. 20231AMENDMENT

SIR:

This Amendment responds to the final Office Action, dated January 7, 2002 rendered in connection with the above-identified patent application. It is respectfully requested that the rejection of claim 2 be reconsidered in view of the following amendments and remarks.

IN THE CLAIMS:

Please amend claim 2 as follows:

2. (Twice Amended) A pharmaceutical tablet composition comprising a pharmaceutically effective amount of N-ethyl-N'-(3-dimethylaminopropyl) urea in combination with a pharmaceutically acceptable carrier.

Please add the following new claims: